Heart Attack Deaths Increasing Among Young Adults
Recent studies show a concerning trend: heart attack deaths among Americans under 55 are on the rise. Dr. Marc Siegel, a senior medical analyst, discusses how we can better care for our hearts amidst this alarming increase.
New research from Columbia University has unveiled a groundbreaking therapy aimed at repairing heart damage after a heart attack. Published in Nature Biomedical Engineering, this study explores an innovative two-step approach that utilizes skeletal muscle to generate a healing molecule that activates upon reaching an injured heart.
Unlike some other organs, the adult heart struggles to heal after a heart attack. Dr. Ke Cheng, the study’s lead author and a professor of biomedical engineering, points out that the heart has limited regenerative abilities. This often leads to damaged muscle being replaced by stiff scar tissue, increasing the risk of heart failure.
Interestingly, newborns have a short period during which their hearts can naturally regenerate. “The neonatal heart produces this healing molecule in greater amounts,” says Dr. Cheng. “Adults, however, can’t produce enough, so we devised a method to supplement this to the heart.”
The technique hinges on a protein known as ANP, which plays a crucial role in heart repair but is generally useless as medication because it dissolves in the bloodstream too quickly. To tackle this, researchers engineered skeletal muscle to act like a factory, producing ANP through a special RNA injection that instructs the muscles to create a “sleeping” version of the protein. This form safely travels through the bloodstream until it reaches the heart, where an enzyme activates it for repair.
In trials conducted on animals, one injection into the limbs led to reduced scarring and improved heart function. The innovative RNA not only directs protein production but also replicates inside the body, ensuring a continuous supply of the healing protein for at least four weeks.
Importantly, the treatment remained effective even when given a week after the initial heart injury, offering hope to those who can’t get immediate treatment. Dr. Cheng noted that this method does not require patients to remain in the hospital for days, minimizing some of the risks associated with direct heart injections.
Though the findings are promising, this therapy is still in the experimental stage, having only been tested in animals. Researchers are eager to see how it will perform in human trials, as human hearts are much more complex. Furthermore, ensuring that prolonged production of this repair protein doesn’t lead to unexpected side effects elsewhere in the body is crucial moving forward.
As the landscape of heart health continues to evolve, staying informed and proactive can play a vital role in reducing risks and improving outcomes for heart attack patients.
